Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(10 sites)
United States
Hoag Memorial Hospital Presbyterian, Newport Beach, California UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California Yale University, Yale Cancer Center, New Haven, Connecticut Beth Israel Deaconess Medical Center, Boston, Massachusetts Dana-Farber Cancer Institute, Boston, Massachusetts Carolina BioOncology Institute, Huntersville, North Carolina The University of Texas MD Anderson Cancer Center, Houston, Texas START, San Antonio, Texas Fred Hutchinson Cancer Center, Seattle, Washington